Sarepta Therapeutics Inc
XBER:AB3A
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sarepta Therapeutics Inc
XBER:AB3A
|
US |
|
Sartorius Stedim Biotech SA
F:56S1
|
FR |
|
Bilfinger SE
OTC:BFLBY
|
DE |
|
E
|
Equinor ASA
XMUN:DNQ
|
NO |
|
Grupo Aeroportuario del Centro Norte SAB de CV
BMV:OMAB
|
MX |
|
C
|
Check Point Software Technologies Ltd
F:CPW
|
IL |
|
WPP PLC
LSE:WPP
|
UK |
|
C
|
Cloudflare Inc
DUS:8CF
|
US |
|
Holcim AG
OTC:HCMLY
|
CH |
|
C
|
Comcast Corp
XBER:CTP2
|
US |
|
Macmahon Holdings Ltd
ASX:MAH
|
AU |
|
V
|
Volkswagen AG
XHAM:VOW
|
DE |
|
Repligen Corp
NASDAQ:RGEN
|
US |
|
Vital Metals Ltd
ASX:VML
|
AU |
|
Barnes Group Inc
NYSE:B
|
US |
|
Yamaha Motor Co Ltd
F:YMA0
|
JP |
|
C
|
Coca-Cola Co
BMV:KO
|
US |
|
B
|
Banco Santander SA
XHAM:BSD2
|
ES |
|
Fresnillo PLC
LSE:FRES
|
MX |
Bankruptcy Probability
Sarepta Therapeutics Inc's probability of bankruptcy is Hidden . The solvency score is Hidden .
We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
Sarepta Therapeutics Inc Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| US |
|
Sarepta Therapeutics Inc
NASDAQ:SRPT
|
1.8B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| JP |
|
Takara Bio Inc
TSE:4974
|
120.4T JPY |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
449.9B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.8B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
166.8B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
123.5B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
71.5B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
46.5B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Sarepta Therapeutics Inc's probability of bankruptcy is Hidden .
The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, Sarepta Therapeutics Inc has total debt of 838.2m USD. This includes both short-term (0 USD) and long-term (838.2m USD) debt.
You can find a full breakdown on its Balance Sheet.
